KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $85.4 million.

  • Biomarin Pharmaceutical's Capital Expenditures rose 54.08% to $28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.8 million, marking a year-over-year decrease of 13.67%. This contributed to the annual value of $85.4 million for FY2024, which is 11.65% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Capital Expenditures of $85.4 million as of FY2024, which was down 11.65% from $96.7 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Capital Expenditures ranged from a high of $121.0 million in FY2022 and a low of $85.4 million during FY2024.
  • Its 3-year average for Capital Expenditures is $101.0 million, with a median of $96.7 million in 2023.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Capital Expenditures dropped by 21.18% in 2020 and then grew by 26.56% in 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's Capital Expenditures (Yearly) stood at $114.3 million in 2020, then dropped by 16.39% to $95.6 million in 2021, then climbed by 26.56% to $121.0 million in 2022, then declined by 20.06% to $96.7 million in 2023, then dropped by 11.65% to $85.4 million in 2024.